Lionel Piroth1, Odile Launay2, Marie-Louise Michel3, Abderrahmane Bourredjem4, Patrick Miailhes5, Faiza Ajana6, Catherine Chirouze7, David Zucman8, Marie-Josee Wendling9, Dani Nazzal2, Fabrice Carrat10, David Rey11, Christine Binquet4. 1. Département d'infectiologie, CHU de Dijon, MERS UMR1347, Université de Bourgogne, Dijon Cedex. 2. Université Paris Descartes, Sorbonne Paris Cité; INSERM, CIC 1417 , F-CRIN, Innovative clinical research network in vaccinology (I-REIVAC), Assistance Publique-Hôpitaux de Paris (AP-HP), Hôpital Cochin, CIC Cochin Pasteur. 3. Laboratoire de Pathogenèse des virus de l'hépatite B, Département de Virologie, Institut Pasteur, INSERM U994, Paris. 4. INSERM, CIC 1432, Centre d'investigation clinique (Epidémiologie clinique/ essais cliniques), CHU de Dijon. 5. Département des Maladies Infectieuses, Hôpital de la Croix-Rousse, Hospices Civils de Lyon, INSERM U1052. 6. Service des Maladies Infectieuses, CHU de Tourcoing. 7. Service des Maladies Infectieuses, CHU de Besançon, Université de Franche-Comté 8. Service de Médecine Interne, Hôpital Foch,Suresnes. 9. Laboratoire de Virologie, Hôpitaux Universitaires, Strasbourg. 10. INSERM, UMR S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique Sorbonne Universités, UPMC Univ Paris 06, UMR S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique Public Health Unit, Saint-Antoine Hospital, AP-HP, Paris. 11. Center for HIV infection care, Hôpitaux Universitaires, Strasbourg Cedex, France.
Abstract
BACKGROUND: Although an isolated anti-hepatitis B virus (HBV) core antibody (anti-HBc) serological profile is frequent in human immunodeficiency virus (HIV)-infected patients, data on HBV vaccination in these patients are scarce. METHODS: A prospective multicenter study was conducted to assess the immunogenicity of HBV vaccination in 54 patients with an isolated anti-HBc profile and undetectable HIV load. They were vaccinated with 1 dose (20 µg) of recombinant HBV vaccine. Those with an anti-HBV surface antibody (anti-HBs) level of <10 mIU/mL 4 weeks after vaccination received 3 additional double doses (40 µg) at weeks 5, 9, and 24. RESULTS: At week 4, 25 patients (46%) were responders. Only the ratio of CD4(+) T cells to CD8(+) T cells was associated with this response in multivariate analysis (odds ratio for +0.1, 1.32; 95% confidence interval, 1.07-1.63; P = .008). At week 28 and month 18, 58% of these patients (14 of 24) and 50% (10 of 20), respectively, maintained anti-HBs level of ≥10 mIU/mL.Among nonresponding patients at week 4, who received further vaccinations, 89% (24 of 27) and 81% (21 of 26) had an anti-HBs level of ≥10 mIU/mL at week 28 and month 18, respectively. The preS2-specific interferon γ T-cell response increased between week 0 and week 28 in patients who finally responded to reinforced vaccination (P = .03). CONCLUSIONS: All of the patients with an isolated anti-HBc profile who did not have an anti-HBs titer of >100 mIU/mL 4 weeks after a single recall dose of HBV vaccine should be further vaccinated with a reinforced triple double-dose scheme.
BACKGROUND: Although an isolated anti-hepatitis B virus (HBV) core antibody (anti-HBc) serological profile is frequent in human immunodeficiency virus (HIV)-infectedpatients, data on HBV vaccination in these patients are scarce. METHODS: A prospective multicenter study was conducted to assess the immunogenicity of HBV vaccination in 54 patients with an isolated anti-HBc profile and undetectable HIV load. They were vaccinated with 1 dose (20 µg) of recombinant HBV vaccine. Those with an anti-HBV surface antibody (anti-HBs) level of <10 mIU/mL 4 weeks after vaccination received 3 additional double doses (40 µg) at weeks 5, 9, and 24. RESULTS: At week 4, 25 patients (46%) were responders. Only the ratio of CD4(+) T cells to CD8(+) T cells was associated with this response in multivariate analysis (odds ratio for +0.1, 1.32; 95% confidence interval, 1.07-1.63; P = .008). At week 28 and month 18, 58% of these patients (14 of 24) and 50% (10 of 20), respectively, maintained anti-HBs level of ≥10 mIU/mL.Among nonresponding patients at week 4, who received further vaccinations, 89% (24 of 27) and 81% (21 of 26) had an anti-HBs level of ≥10 mIU/mL at week 28 and month 18, respectively. The preS2-specific interferon γ T-cell response increased between week 0 and week 28 in patients who finally responded to reinforced vaccination (P = .03). CONCLUSIONS: All of the patients with an isolated anti-HBc profile who did not have an anti-HBs titer of >100 mIU/mL 4 weeks after a single recall dose of HBV vaccine should be further vaccinated with a reinforced triple double-dose scheme.
Authors: Norah A Terrault; Anna S F Lok; Brian J McMahon; Kyong-Mi Chang; Jessica P Hwang; Maureen M Jonas; Robert S Brown; Natalie H Bzowej; John B Wong Journal: Hepatology Date: 2018-04 Impact factor: 17.425
Authors: Zoe Moodie; Stephen R Walsh; Fatima Laher; Lucas Maganga; Michael E Herce; Sarita Naidoo; Mina C Hosseinipour; Craig Innes; Linda-Gail Bekker; Nicole Grunenberg; Philipp Mann; Chenchen Yu; Allan C deCamp; Maurine D Miner; Nicole L Yates; Jack Heptinstall; Nonhlanhla N Mkhize; One Dintwe; Nicole Frahm; Kristen W Cohen; Mary Allen; Julia Hutter; Ralf Wagner; Giuseppe Pantaleo; M Juliana McElrath; Georgia D Tomaras; Lynn Morris; David C Montefiori; Erica Andersen-Nissen; Glenda E Gray; Peter B Gilbert; James G Kublin Journal: PLoS Med Date: 2020-05-22 Impact factor: 11.069
Authors: Anupriya Dutta; Hajime Uno; David R Lorenz; Steven M Wolinsky; Dana Gabuzda Journal: Cancer Causes Control Date: 2018-10-12 Impact factor: 2.532